Hepatic overexpression of LCN2 protects against HFCF‐induced NAFLD by promoting lipolysis and fatty acid oxidation by increasing proliferator‐activated receptor alpha activity.35 This evidence concerns the gene LCN2 and metabolic dysfunction-associated steatotic liver disease.